ID G6PE_HUMAN Reviewed; 791 AA. AC O95479; Q4TT33; Q66I35; Q68DT3; R4GMU1; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2006, sequence version 2. DT 27-MAR-2024, entry version 194. DE RecName: Full=GDH/6PGL endoplasmic bifunctional protein {ECO:0000250|UniProtKB:Q8CFX1}; DE Includes: DE RecName: Full=Hexose-6-phosphate dehydrogenase {ECO:0000303|PubMed:10349511}; DE AltName: Full=Glucose 1-dehydrogenase {ECO:0000303|PubMed:10349511}; DE Short=GDH {ECO:0000303|PubMed:10349511}; DE EC=1.1.1.47 {ECO:0000250|UniProtKB:Q8CFX1}; DE AltName: Full=Glucose-6-phosphate dehydrogenase {ECO:0000305|PubMed:18628520}; DE EC=1.1.1.363 {ECO:0000269|PubMed:18628520}; DE Includes: DE RecName: Full=6-phosphogluconolactonase {ECO:0000250|UniProtKB:Q8CFX1}; DE Short=6PGL {ECO:0000250|UniProtKB:Q8CFX1}; DE EC=3.1.1.31 {ECO:0000250|UniProtKB:Q8CFX1}; DE Flags: Precursor; GN Name=H6PD {ECO:0000312|HGNC:HGNC:4795}; Synonyms=GDH; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RC TISSUE=Bone marrow; RX PubMed=10349511; DOI=10.1006/bcmd.1999.0224; RA Mason P.J., Stevens D., Diez A., Knight S.W., Scopes D.A., Vulliamy T.J.; RT "Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded RT at 1p36: coding sequence and expression."; RL Blood Cells Mol. Dis. 25:30-36(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), VARIANT CORTRD1 RP GLN-453, AND VARIANT ALA-151. RC TISSUE=Salivary gland; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-453. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-157 AND ASN-282. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [8] RP VARIANT CORTRD1 GLN-453, CHARACTERIZATION OF VARIANT CORTRD1 GLN-453, RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=12858176; DOI=10.1038/ng1214; RA Draper N., Walker E.A., Bujalska I.J., Tomlinson J.W., Chalder S.M., RA Arlt W., Lavery G.G., Bedendo O., Ray D.W., Laing I., Malunowicz E., RA White P.C., Hewison M., Mason P.J., Connell J.M., Shackleton C.H.L., RA Stewart P.M.; RT "Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 RT and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase RT deficiency."; RL Nat. Genet. 34:434-439(2003). RN [9] RP VARIANTS CORTRD1 316-TYR--GLY-791 DEL AND ASP-359, CHARACTERIZATION OF RP VARIANTS CORTRD1 316-TYR--GLY-791 DEL; ASP-359 AND GLN-453, FUNCTION, RP CATALYTIC ACTIVITY, PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=18628520; DOI=10.1210/jc.2008-0743; RA Lavery G.G., Walker E.A., Tiganescu A., Ride J.P., Shackleton C.H., RA Tomlinson J.W., Connell J.M., Ray D.W., Biason-Lauber A., Malunowicz E.M., RA Arlt W., Stewart P.M.; RT "Steroid biomarkers and genetic studies reveal inactivating mutations in RT hexose-6-phosphate dehydrogenase in patients with cortisone reductase RT deficiency."; RL J. Clin. Endocrinol. Metab. 93:3827-3832(2008). RN [10] RP VARIANTS CORTRD1 LEU-146; 325-GLN--GLY-791 DEL AND 446-TYR--GLY-791 DEL, RP CHARACTERIZATION OF VARIANTS CORTRD1 LEU-146; 325-GLN--GLY-791 DEL AND RP 446-TYR--GLY-791 DEL, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=23132696; DOI=10.1530/eje-12-0628; RA Lavery G.G., Idkowiak J., Sherlock M., Bujalska I., Ride J.P., Saqib K., RA Hartmann M.F., Hughes B., Wudy S.A., De Schepper J., Arlt W., Krone N., RA Shackleton C.H., Walker E.A., Stewart P.M.; RT "Novel H6PDH mutations in two girls with premature adrenarche: 'apparent' RT and 'true' CRD can be differentiated by urinary steroid profiling."; RL Eur. J. Endocrinol. 168:K19-K26(2013). CC -!- FUNCTION: Bifunctional enzyme localized in the lumen of the endoplasmic CC reticulum that catalyzes the first two steps of the oxidative branch of CC the pentose phosphate pathway/shunt, an alternative to glycolysis and a CC major source of reducing power and metabolic intermediates for CC biosynthetic processes (By similarity). Has a hexose-6-phosphate CC dehydrogenase activity, with broad substrate specificity compared to CC glucose-6-phosphate 1-dehydrogenase/G6PD, and catalyzes the first step CC of the pentose phosphate pathway (PubMed:12858176, PubMed:18628520, CC PubMed:23132696). In addition, acts as a 6-phosphogluconolactonase and CC catalyzes the second step of the pentose phosphate pathway (By CC similarity). May have a dehydrogenase activity for alternative CC substrates including glucosamine 6-phosphate and glucose 6-sulfate (By CC similarity). The main function of this enzyme is to provide reducing CC equivalents such as NADPH to maintain the adequate levels of reductive CC cofactors in the oxidizing environment of the endoplasmic reticulum CC (PubMed:12858176, PubMed:18628520, PubMed:23132696). By producing NADPH CC that is needed by reductases of the lumen of the endoplasmic reticulum CC like corticosteroid 11-beta-dehydrogenase isozyme 1/HSD11B1, indirectly CC regulates their activity (PubMed:18628520). CC {ECO:0000250|UniProtKB:Q8CFX1, ECO:0000269|PubMed:12858176, CC ECO:0000269|PubMed:18628520, ECO:0000269|PubMed:23132696}. CC -!- CATALYTIC ACTIVITY: CC Reaction=D-glucose 6-phosphate + NADP(+) = 6-phospho-D-glucono-1,5- CC lactone + H(+) + NADPH; Xref=Rhea:RHEA:15841, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57783, ChEBI:CHEBI:57955, ChEBI:CHEBI:58349, CC ChEBI:CHEBI:61548; EC=1.1.1.363; CC Evidence={ECO:0000269|PubMed:18628520, ECO:0000269|PubMed:23132696}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15842; CC Evidence={ECO:0000305|PubMed:18628520}; CC -!- CATALYTIC ACTIVITY: CC Reaction=D-glucose 6-phosphate + NAD(+) = 6-phospho-D-glucono-1,5- CC lactone + H(+) + NADH; Xref=Rhea:RHEA:38215, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:57955, CC ChEBI:CHEBI:61548; EC=1.1.1.363; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38216; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=6-phospho-D-glucono-1,5-lactone + H2O = 6-phospho-D-gluconate CC + H(+); Xref=Rhea:RHEA:12556, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57955, ChEBI:CHEBI:58759; EC=3.1.1.31; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12557; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-deoxy-D-glucose 6-phosphate + NAD(+) = 2-deoxy-6-phospho-D- CC glucono-1,5-lactone + H(+) + NADH; Xref=Rhea:RHEA:62064, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, CC ChEBI:CHEBI:84760, ChEBI:CHEBI:145420; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62065; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-deoxy-D-glucose 6-phosphate + NADP(+) = 2-deoxy-6-phospho-D- CC glucono-1,5-lactone + H(+) + NADPH; Xref=Rhea:RHEA:62068, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, CC ChEBI:CHEBI:84760, ChEBI:CHEBI:145420; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62069; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=D-galactose 6-phosphate + NADP(+) = 6-phospho-D-galactono-1,5- CC lactone + H(+) + NADPH; Xref=Rhea:RHEA:62072, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:91004, CC ChEBI:CHEBI:145419; Evidence={ECO:0000269|PubMed:12858176}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62073; CC Evidence={ECO:0000305|PubMed:12858176}; CC -!- CATALYTIC ACTIVITY: CC Reaction=D-galactose 6-phosphate + NAD(+) = 6-phospho-D-galactono-1,5- CC lactone + H(+) + NADH; Xref=Rhea:RHEA:62076, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:91004, CC ChEBI:CHEBI:145419; Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62077; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=D-glucosamine 6-phosphate + NADP(+) = 2-amino-2-deoxy-6- CC phospho-D-glucono-1,5-lactone + 2 H(+) + NADPH; Xref=Rhea:RHEA:62088, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, CC ChEBI:CHEBI:58725, ChEBI:CHEBI:145423; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62089; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=D-glucose + NAD(+) = D-glucono-1,5-lactone + H(+) + NADH; CC Xref=Rhea:RHEA:14293, ChEBI:CHEBI:4167, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:16217, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.47; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14294; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=D-glucose + NADP(+) = D-glucono-1,5-lactone + H(+) + NADPH; CC Xref=Rhea:RHEA:14405, ChEBI:CHEBI:4167, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:16217, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.47; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14406; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- CATALYTIC ACTIVITY: CC Reaction=D-glucose 6-sulfate + NADP(+) = 6-sulfo-D-glucono-1,5-lactone CC + H(+) + NADPH; Xref=Rhea:RHEA:62080, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:145424, CC ChEBI:CHEBI:145427; Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62081; CC Evidence={ECO:0000250|UniProtKB:Q8CFX1}; CC -!- PATHWAY: Carbohydrate degradation; pentose phosphate pathway; D- CC ribulose 5-phosphate from D-glucose 6-phosphate (oxidative stage): step CC 1/3. {ECO:0000269|PubMed:12858176, ECO:0000269|PubMed:18628520, CC ECO:0000269|PubMed:23132696}. CC -!- PATHWAY: Carbohydrate degradation; pentose phosphate pathway; D- CC ribulose 5-phosphate from D-glucose 6-phosphate (oxidative stage): step CC 2/3. {ECO:0000250|UniProtKB:Q8CFX1}. CC -!- PATHWAY: Carbohydrate degradation; pentose phosphate pathway; D- CC ribulose 5-phosphate from D-glucose 6-phosphate (oxidative stage). CC {ECO:0000250|UniProtKB:Q8CFX1}. CC -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:Q8CFX1}. CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum lumen CC {ECO:0000305|PubMed:18628520}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O95479-1; Sequence=Displayed; CC Name=2; CC IsoId=O95479-2; Sequence=VSP_060485; CC -!- TISSUE SPECIFICITY: Present in most tissues examined, strongest in CC liver. {ECO:0000269|PubMed:10349511}. CC -!- DISEASE: Cortisone reductase deficiency 1 (CORTRD1) [MIM:604931]: An CC autosomal recessive error of cortisone metabolism characterized by a CC failure to regenerate cortisol from cortisone, resulting in increased CC cortisol clearance, activation of the hypothalamic-pituitary axis and CC ACTH-mediated adrenal androgen excess. Clinical features include CC hyperandrogenism resulting in hirsutism, oligo-amenorrhea, and CC infertility in females and premature pseudopuberty in males. CC {ECO:0000269|PubMed:12858176, ECO:0000269|PubMed:17974005, CC ECO:0000269|PubMed:18628520, ECO:0000269|PubMed:23132696}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: In the N-terminal section; belongs to the glucose-6- CC phosphate dehydrogenase family. {ECO:0000305}. CC -!- SIMILARITY: In the C-terminal section; belongs to the CC glucosamine/galactosamine-6-phosphate isomerase family. 6- CC phosphogluconolactonase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and CC polymorphism database; CC URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=C&genename=H6PD"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ012590; CAA10071.1; -; mRNA. DR EMBL; CR749282; CAH18137.1; -; mRNA. DR EMBL; Z98044; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC081559; AAH81559.1; -; mRNA. DR CCDS; CCDS101.1; -. [O95479-1] DR CCDS; CCDS72697.1; -. [O95479-2] DR RefSeq; NP_001269516.1; NM_001282587.1. [O95479-2] DR RefSeq; NP_004276.2; NM_004285.3. [O95479-1] DR RefSeq; XP_006711115.1; XM_006711052.3. [O95479-1] DR RefSeq; XP_016858354.1; XM_017002865.1. [O95479-1] DR PDB; 8EM2; EM; 3.02 A; A/B=1-791. DR PDBsum; 8EM2; -. DR AlphaFoldDB; O95479; -. DR EMDB; EMD-26425; -. DR EMDB; EMD-28232; -. DR SMR; O95479; -. DR BioGRID; 114933; 39. DR IntAct; O95479; 4. DR STRING; 9606.ENSP00000473348; -. DR BindingDB; O95479; -. DR DrugBank; DB00157; NADH. DR GlyConnect; 1264; 3 N-Linked glycans (1 site). DR GlyCosmos; O95479; 3 sites, 3 glycans. DR GlyGen; O95479; 3 sites, 5 N-linked glycans (2 sites). DR iPTMnet; O95479; -. DR PhosphoSitePlus; O95479; -. DR SwissPalm; O95479; -. DR BioMuta; H6PD; -. DR EPD; O95479; -. DR jPOST; O95479; -. DR MassIVE; O95479; -. DR MaxQB; O95479; -. DR PaxDb; 9606-ENSP00000473348; -. DR PeptideAtlas; O95479; -. DR ProteomicsDB; 50910; -. DR Pumba; O95479; -. DR Antibodypedia; 1350; 350 antibodies from 28 providers. DR DNASU; 9563; -. DR Ensembl; ENST00000377403.7; ENSP00000366620.2; ENSG00000049239.13. [O95479-1] DR Ensembl; ENST00000602477.1; ENSP00000473348.1; ENSG00000049239.13. [O95479-2] DR GeneID; 9563; -. DR KEGG; hsa:9563; -. DR MANE-Select; ENST00000377403.7; ENSP00000366620.2; NM_004285.4; NP_004276.2. DR UCSC; uc001apt.4; human. [O95479-1] DR AGR; HGNC:4795; -. DR CTD; 9563; -. DR DisGeNET; 9563; -. DR GeneCards; H6PD; -. DR HGNC; HGNC:4795; H6PD. DR HPA; ENSG00000049239; Tissue enhanced (liver). DR MalaCards; H6PD; -. DR MIM; 138090; gene. DR MIM; 604931; phenotype. DR neXtProt; NX_O95479; -. DR OpenTargets; ENSG00000049239; -. DR Orphanet; 168588; Hyperandrogenism due to cortisone reductase deficiency. DR PharmGKB; PA29170; -. DR VEuPathDB; HostDB:ENSG00000049239; -. DR eggNOG; KOG0563; Eukaryota. DR eggNOG; KOG3147; Eukaryota. DR GeneTree; ENSGT00530000063435; -. DR HOGENOM; CLU_018975_0_0_1; -. DR InParanoid; O95479; -. DR OrthoDB; 989808at2759; -. DR PhylomeDB; O95479; -. DR TreeFam; TF354247; -. DR BioCyc; MetaCyc:HS00614-MONOMER; -. DR PathwayCommons; O95479; -. DR SABIO-RK; O95479; -. DR SignaLink; O95479; -. DR UniPathway; UPA00115; UER00408. DR UniPathway; UPA00115; UER00409. DR BioGRID-ORCS; 9563; 4 hits in 1146 CRISPR screens. DR ChiTaRS; H6PD; human. DR GeneWiki; H6PD; -. DR GenomeRNAi; 9563; -. DR Pharos; O95479; Tbio. DR PRO; PR:O95479; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; O95479; Protein. DR Bgee; ENSG00000049239; Expressed in parotid gland and 197 other cell types or tissues. DR GO; GO:0005783; C:endoplasmic reticulum; IBA:GO_Central. DR GO; GO:0005788; C:endoplasmic reticulum lumen; IDA:UniProtKB. DR GO; GO:0017057; F:6-phosphogluconolactonase activity; ISS:UniProtKB. DR GO; GO:0030246; F:carbohydrate binding; IEA:Ensembl. DR GO; GO:0047934; F:glucose 1-dehydrogenase (NAD+) activity; IEA:RHEA. DR GO; GO:0047935; F:glucose 1-dehydrogenase (NADP+) activity; IEA:RHEA. DR GO; GO:0047936; F:glucose 1-dehydrogenase [NAD(P)] activity; IEA:UniProtKB-EC. DR GO; GO:0004345; F:glucose-6-phosphate dehydrogenase activity; IDA:UniProtKB. DR GO; GO:0050661; F:NADP binding; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IBA:GO_Central. DR GO; GO:0009051; P:pentose-phosphate shunt, oxidative branch; IMP:UniProtKB. DR GO; GO:2000064; P:regulation of cortisol biosynthetic process; IMP:UniProtKB. DR GO; GO:0097305; P:response to alcohol; IEA:Ensembl. DR GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl. DR CDD; cd01400; 6PGL; 1. DR Gene3D; 3.40.50.1360; -; 1. DR Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1. DR InterPro; IPR005900; 6-phosphogluconolactonase_DevB. DR InterPro; IPR001282; G6P_DH. DR InterPro; IPR019796; G6P_DH_AS. DR InterPro; IPR022675; G6P_DH_C. DR InterPro; IPR022674; G6P_DH_NAD-bd. DR InterPro; IPR006148; Glc/Gal-6P_isomerase. DR InterPro; IPR036291; NAD(P)-bd_dom_sf. DR InterPro; IPR037171; NagB/RpiA_transferase-like. DR NCBIfam; TIGR01198; pgl; 1. DR PANTHER; PTHR23429:SF7; GDH_6PGL ENDOPLASMIC BIFUNCTIONAL PROTEIN; 1. DR PANTHER; PTHR23429; GLUCOSE-6-PHOSPHATE 1-DEHYDROGENASE G6PD; 1. DR Pfam; PF02781; G6PD_C; 1. DR Pfam; PF00479; G6PD_N; 1. DR Pfam; PF01182; Glucosamine_iso; 1. DR PRINTS; PR00079; G6PDHDRGNASE. DR SUPFAM; SSF55347; Glyceraldehyde-3-phosphate dehydrogenase-like, C-terminal domain; 1. DR SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1. DR SUPFAM; SSF100950; NagB/RpiA/CoA transferase-like; 1. DR PROSITE; PS00069; G6P_DEHYDROGENASE; 1. DR Genevisible; O95479; HS. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Carbohydrate metabolism; KW Disease variant; Endoplasmic reticulum; Glucose metabolism; Glycoprotein; KW Hydrolase; Multifunctional enzyme; NAD; NADP; Oxidoreductase; KW Pyrrolidone carboxylic acid; Reference proteome; Signal. FT SIGNAL 1..19 FT /evidence="ECO:0000250|UniProtKB:P56201" FT CHAIN 20..791 FT /note="GDH/6PGL endoplasmic bifunctional protein" FT /id="PRO_0000010442" FT REGION 20..526 FT /note="Hexose-6-phosphate dehydrogenase" FT /evidence="ECO:0000305" FT REGION 527..540 FT /note="Linker" FT /evidence="ECO:0000305" FT REGION 541..791 FT /note="6-phosphogluconolactonase" FT /evidence="ECO:0000305" FT ACT_SITE 267 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P11411" FT BINDING 32..39 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 149 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 174 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 174 FT /ligand="substrate" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 204..208 FT /ligand="substrate" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 243 FT /ligand="substrate" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 262 FT /ligand="substrate" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 360 FT /ligand="substrate" FT /evidence="ECO:0000250|UniProtKB:P11413" FT BINDING 365 FT /ligand="substrate" FT /evidence="ECO:0000250|UniProtKB:P11413" FT MOD_RES 20 FT /note="Pyrrolidone carboxylic acid" FT /evidence="ECO:0000250|UniProtKB:P56201" FT MOD_RES 208 FT /note="N6-succinyllysine" FT /evidence="ECO:0000250|UniProtKB:Q8CFX1" FT CARBOHYD 157 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 683 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1 FT /note="M -> MLAEPFNWHPGM (in isoform 2)" FT /id="VSP_060485" FT VARIANT 146 FT /note="P -> L (in CORTRD1; no effect on protein abundance; FT decreased glucose-6-phosphate dehydrogenase activity)" FT /evidence="ECO:0000269|PubMed:23132696" FT /id="VAR_069193" FT VARIANT 151 FT /note="D -> A (in dbSNP:rs34603401)" FT /evidence="ECO:0000269|PubMed:17974005" FT /id="VAR_049117" FT VARIANT 218 FT /note="R -> Q (in dbSNP:rs35525021)" FT /id="VAR_049118" FT VARIANT 316..791 FT /note="Missing (in CORTRD1; loss of glucose-6-phosphate FT dehydrogenase activity)" FT /evidence="ECO:0000269|PubMed:18628520" FT /id="VAR_083053" FT VARIANT 325..791 FT /note="Missing (in CORTRD1; loss of glucose-6-phosphate FT dehydrogenase activity)" FT /evidence="ECO:0000269|PubMed:23132696" FT /id="VAR_083054" FT VARIANT 359 FT /note="G -> D (in CORTRD1; loss of glucose-6-phosphate FT dehydrogenase activity; dbSNP:rs387907167)" FT /evidence="ECO:0000269|PubMed:18628520" FT /id="VAR_083055" FT VARIANT 446..791 FT /note="Missing (in CORTRD1; loss of glucose-6-phosphate FT dehydrogenase activity)" FT /evidence="ECO:0000269|PubMed:23132696" FT /id="VAR_083056" FT VARIANT 453 FT /note="R -> Q (in CORTRD1; uncertain significance; no FT effect on glucose-6-phosphate dehydrogenase activity; FT however an effect was originally observed; FT dbSNP:rs6688832)" FT /evidence="ECO:0000269|PubMed:12858176, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005, FT ECO:0000269|PubMed:18628520" FT /id="VAR_026487" FT VARIANT 484 FT /note="N -> D (in dbSNP:rs35404275)" FT /id="VAR_049119" FT VARIANT 554 FT /note="P -> L (in dbSNP:rs17368528)" FT /id="VAR_049120" FT CONFLICT 339 FT /note="A -> G (in Ref. 1; CAA10071)" FT /evidence="ECO:0000305" FT STRAND 25..30 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 36..40 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 42..53 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 60..68 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 70..82 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 92..105 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 112..114 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 115..131 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 135..141 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 150..158 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 163..165 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 170..172 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 180..191 FT /evidence="ECO:0007829|PDB:8EM2" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 200..202 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 205..207 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 211..213 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 214..219 FT /evidence="ECO:0007829|PDB:8EM2" FT TURN 223..228 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 231..233 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 234..242 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 247..249 FT /evidence="ECO:0007829|PDB:8EM2" FT TURN 252..257 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 258..262 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 263..267 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 268..275 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 287..298 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 308..313 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 314..323 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 336..342 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 346..351 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 354..361 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 366..373 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 383..385 FT /evidence="ECO:0007829|PDB:8EM2" FT TURN 388..390 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 392..394 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 397..404 FT /evidence="ECO:0007829|PDB:8EM2" FT TURN 405..407 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 411..415 FT /evidence="ECO:0007829|PDB:8EM2" FT TURN 416..418 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 443..445 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 446..453 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 457..467 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 470..472 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 476..492 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:8EM2" FT HELIX 504..506 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 513..516 FT /evidence="ECO:0007829|PDB:8EM2" FT STRAND 519..524 FT /evidence="ECO:0007829|PDB:8EM2" SQ SEQUENCE 791 AA; 88893 MW; 01E179BE00C87C79 CRC64; MWNMLIVAMC LALLGCLQAQ ELQGHVSIIL LGATGDLAKK YLWQGLFQLY LDEAGRGHSF SFHGAALTAP KQGQELMAKA LESLSCPKDM APSHCAEHKD QFLQLSQYRQ LKTAEDYQAL NKDIEAQLQH AGLREAGRIF YFSVPPFAYE DIARNINSSC RPGPGAWLRV VLEKPFGHDH FSAQQLATEL GTFFQEEEMY RVDHYLGKQA VAQILPFRDQ NRKALDGLWN RHHVERVEII MKETVDAEGR TSFYEEYGVI RDVLQNHLTE VLTLVAMELP HNVSSAEAVL RHKLQVFQAL RGLQRGSAVV GQYQSYSEQV RRELQKPDSF HSLTPTFAAV LVHIDNLRWE GVPFILMSGK ALDERVGYAR ILFKNQACCV QSEKHWAAAQ SQCLPRQLVF HIGHGDLGSP AVLVSRNLFR PSLPSSWKEM EGPPGLRLFG SPLSDYYAYS PVRERDAHSV LLSHIFHGRK NFFITTENLL ASWNFWTPLL ESLAHKAPRL YPGGAENGRL LDFEFSSGRL FFSQQQPEQL VPGPGPAPMP SDFQVLRAKY RESPLVSAWS EELISKLAND IEATAVRAVR RFGQFHLALS GGSSPVALFQ QLATAHYGFP WAHTHLWLVD ERCVPLSDPE SNFQGLQAHL LQHVRIPYYN IHPMPVHLQQ RLCAEEDQGA QIYAREISAL VANSSFDLVL LGMGADGHTA SLFPQSPTGL DGEQLVVLTT SPSQPHRRMS LSLPLINRAK KVAVLVMGRM KREITTLVSR VGHEPKKWPI SGVLPHSGQL VWYMDYDAFL G //